Pancragen Peptide (20mg)

Pancragen Research

Pancragen (KEDW) is a tetrapeptide bioregulator that directly interacts with DNA to regulate pancreatic gene expression and cellular development. Research demonstrates its unique mechanisms in glucose metabolism, stem cell differentiation, and age-related pancreatic function restoration.

Gene Expression and DNA Interaction

Pancragen peptide binds directly to DNA along the major groove, creating stable peptide-DNA complexes that regulate gene transcription. This binding mechanism enables precise interaction with regulatory elements controlling pancreatic cell development[1].

The peptide increases expression of critical pancreatic genes including PDX1, NGN3, PAX6, FOXA2, NKX2-2, NKX6.1, and PAX4. These transcription factors represent fundamental regulators of pancreatic endocrine cell fate and β-cell development[1].

Physical spectroscopy and molecular modeling confirm that Pancragen forms three-dimensional stable complexes with DNA through specific binding interactions. This mechanism suggests the peptide functions as an epigenetic modulator influencing chromatin accessibility and transcriptional programs[1].

Metabolic Function Research

Clinical research demonstrates that Pancragen reduces plasma glucose levels during fasting and oral glucose tolerance tests in elderly patients with type 2 diabetes. The metabolic benefits persist for at least two weeks after treatment cessation in approximately 60% of patients[2].

The peptide enhances insulin sensitivity by decreasing HOMA insulin resistance index values. This improvement occurs particularly in patients with high baseline insulin resistance and hyperinsulinemia[2].

Glucose-lowering effects have been confirmed in both streptozotocin-induced and alloxan-induced diabetes models. These different experimental diabetes models indicate that Pancragen’s effects operate through multiple pathways rather than targeting a single aspect of glucose homeostasis.

Stem Cell and Regenerative Applications

Pancragen modulates stem cell fate in tissue engineering applications, directing differentiation toward pancreatic lineages including hepatocyte and endocrine cell types[3]. The peptide can cross cell membranes and interact with intracellular targets, making it useful for directing stem cell differentiation in three-dimensional culture systems.

The peptide’s biocompatibility and biodegradability position it as an ideal candidate for regenerative medicine applications. Its ability to self-assemble and create extracellular matrix-like environments makes it valuable for stem cell microenvironments that promote specific differentiation outcomes.

Developmental Biology

KEDW peptide regulates key developmental transcription factors crucial for pancreatic organogenesis. PDX1 upregulation is particularly significant, as PDX1 represents the earliest marker of pancreatic progenitor cells and is essential for proper pancreatic development[1].

The peptide enhances NGN3 (Neurogenin 3) expression, a transcription factor marking endocrine progenitor cells essential for all pancreatic endocrine cell types. These transcription factors work in hierarchical pathways to determine pancreatic cell fate specification[1].

Age-Related Function Research

Pancragen restores age-related disturbances in pancreatic endocrine function, particularly addressing metabolic decline in elderly populations. The aging pancreas undergoes morphological and functional changes that contribute to glucose homeostasis dysregulation[4].

The peptide’s effects involve restoration of cellular differentiation capacity that typically declines with age[5]. Clinical studies demonstrate sustained metabolic improvements that persist beyond the treatment period, suggesting long-term changes in pancreatic cell function[2].

References

1. V. Kh. Khavinson, S. M. Tendler, N. A. Kasyanenko, and S. I. Tarnovskaya, “Tetrapeptide KEDW Interacts with DNA and Regulates Gene Expression,” New World Publishing International, Inc., Jul. 2015. doi: 10.5099/aj150300156. https://doi.org/10.5099/aj150300156
2. O. V. Korkushko, V. B. Shatilo, W. H. Havinson, and I. A. Antonyuk-Shcheglova, “EFFICACY OF PANCRAGEN PEPTIDE IN ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS,” V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU, Oct. 2010. doi: 10.21856/j-pep.2010.3.01. https://doi.org/10.21856/j-pep.2010.3.01
3. R. Vishwanath, A. Biswas, U. Modi, S. Gupta, D. Bhatia, and R. Solanki, “Programmable short peptides for modulating stem cell fate in tissue engineering and regenerative medicine,” Royal Society of Chemistry (RSC), 2025. doi: 10.1039/d4tb02102a. https://doi.org/10.1039/d4tb02102a
4. O. V. Korkushko, V. Kh. Khavinson, V. B. Shatilo, I. A. Antonyk-Sheglova, and E. V. Bondarenko, “Prospects of Using Pancragen for Correction of Metabolic Disorders in Elderly People,” Springer Science and Business Media LLC, Aug. 2011. doi: 10.1007/s10517-011-1354-4. https://doi.org/10.1007/s10517-011-1354-4
5. V. Kh. Khavinson et al., “Effects of Pancragen on The Differentiation of Pancreatic Cells During Their Ageing,” Springer Science and Business Media LLC, Feb. 2013. doi: 10.1007/s10517-013-1987-6. https://doi.org/10.1007/s10517-013-1987-6